# CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

> **NCT04891718** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Presage Biosciences**

## Conditions studied

- Solid Tumour

## Interventions

- **BIOLOGICAL:** MVC-101
- **BIOLOGICAL:** Nivolumab
- **COMBINATION_PRODUCT:** MVC-101 + Nivolumab

## Key facts

- **NCT ID:** NCT04891718
- **Lead sponsor:** Presage Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-15
- **Primary completion:** 2022-06-05
- **Final completion:** 2022-06-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Termination by pharmaceutical sponsor
- **Last updated:** 2022-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891718, "CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04891718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*